

















CLAIMS

1. A composition comprising a salt of a compound selected from the following table:







YDE-001	 Hyp Gly Gln Glu Gly Leu Ala Gly Pro Lys <i>(2S,4R)</i>
YDE-008	 Hyp Gly Gln Ala Gly Leu Ala Gly Pro Lys <i>(2S,4R)</i>
YDE-011	 Hyp Gly Gln Leu Gly Leu Ala Gly Pro Lys <i>(2S,4R)</i>
YDE-015	 Hyp Gly Gln Asp Val Leu Ala Gly Pro Lys <i>(2S,4R)</i>
YDE-016	 Hyp Gly Gln Asp Ile Leu Ala Gly Pro Lys <i>(2S,4R)</i>







YDE-023	 Hyp Gly Gln Asp Ser Leu Ala Gly Pro Lys (2S,4R)
YDE-026	 Hyp Gly Gln Homo-Ser Gly Leu Ala Gly Pro Lys (2S,4R)
YDE-038	 (4-hydroxyMe)Pro Gly Gln Leu Gly Leu Ala Gly Pro Lys (2S,4R)
YDE-044	 (4-Me)Pro Gly Gln Leu Gly Leu Ala Gly Pro Lys
YDE-045	 (5-Me)Pro Gly Gln Leu Gly Leu Ala Gly Pro Lys
YDE-048	 Hyp Ala Gln Leu Gly Leu Ala Gly Pro Lys




YDE-049	 Hyp Gly Ala Leu Gly Leu Ala Gly Pro Lys
YDE-054	 Hyp Gly Gln Leu Gly Leu Ala Ala Pro Lys
YDE-057	 D-Hyp Gly Gln Leu Gly Leu Ala Gly Pro Lys (2R,4S)
YDE-058	 D-Hyp Gly D-Gln D-Leu Gly D-Leu D-Ala Gly D-Pro D-Lys (2R,4S)
YDE-060	 D-Hyp Gly D-Gln D-Leu Gly D-Leu D-Ala Gly D-Pro D-Lys (2R,4R)

wherein at least 90% of the compound in the composition is present as the salt; and wherein the salt is derived from hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, perchloric acid, phosphoric acid, formic acid, acetic acid, lactic acid, malic acid, fumaric acid, succinic acid, tartaric acid, glycolic acid, salicylic acid, citric acid, methanesulfonic acid, benzenesulfonic acid, benzoic acid, malonic acid, trichloroacetic acid, naphthalene-2-sulfonic acid, oxalic acid, or mandelic acid.



2. The composition of claim 1, wherein the compound is selected from the following table:







YDE-001	 Hyp (2S,4R) Gly Gln Glu Gly Leu Ala Gly Pro Lys NH₂
YDE-008	 Hyp (2S,4R) Gly Gln Ala Gly Leu Ala Gly Pro Lys NH₂
YDE-011	 Hyp (2S,4R) Gly Gln Leu Gly Leu Ala Gly Pro Lys NH₂
YDE-015	 Hyp (2S,4R) Gly Gln Asp Val Leu Ala Gly Pro Lys NH₂
YDE-016	 Hyp (2S,4R) Gly Gln Asp Ile Leu Ala Gly Pro Lys NH₂
YDE-023	 Hyp (2S,4R) Gly Gln Asp Ser Leu Ala Gly Pro Lys NH₂


YDE-026	 Hyp Gly Gln Homo-Ser Gly Leu Ala Gly Pro Lys (2S,4R)
YDE-038	 (4-hydroxyMe)Pro Gly Gln Leu Gly Leu Ala Gly Pro Lys (2S,4R)
YDE-044	 (4-Me)Pro Gly Gln Leu Gly Leu Ala Gly Pro Lys
YDE-045	 (5-Me)Pro Gly Gln Leu Gly Leu Ala Gly Pro Lys
YDE-049	 Hyp Gly Ala Leu Gly Leu Ala Gly Pro Lys
YDE-054	 Hyp Gly Gln Leu Gly Leu Ala Ala Pro Lys

YDE-057	 D-Hyp (2R,4S) Gly Gln Leu Gly Leu Ala Gly Pro Lys
YDE-058	 D-Hyp (2R,4S) Gly D-Gln D-Leu Gly D-Leu D-Ala Gly D-Pro D-Lys
YDE-060	 D-Hyp (2R,4R) Gly D-Gln D-Leu Gly D-Leu D-Ala Gly D-Pro D-Lys


3. The composition of claim 2, wherein the compound is selected from the following table:

YDE-001	 Hyp (2S,4R) Gly Gln Glu Gly Leu Ala Gly Pro Lys
YDE-008	 Hyp (2S,4R) Gly Gln Ala Gly Leu Ala Gly Pro Lys


YDE-011	 Hyp Gly Gln Leu Gly Leu Ala Gly Pro Lys NH₂ (2S,4R)
YDE-015	 Hyp Gly Gln Asp Val Leu Ala Gly Pro Lys NH₂ (2S,4R)
YDE-016	 Hyp Gly Gln Asp Ile Leu Ala Gly Pro Lys NH₂ (2S,4R)
YDE-023	 Hyp Gly Gln Asp Ser Leu Ala Gly Pro Lys NH₂ (2S,4R)
YDE-026	 Hyp Gly Gln Homo-Ser Gly Leu Ala Gly Pro Lys NH₂ (2S,4R)
YDE-038	 (4-hydroxyMe)Pro Gly Gln Leu Gly Leu Ala Gly Pro Lys NH₂ (2S,4R)




4. The composition of claim 3, wherein the compound is selected from the following table:



5. The composition of claim 4, wherein the compound has the structure:





6. The composition of claim 4, wherein the compound has the structure:






7. The composition of claim 1, wherein the compound is selected from the following table:


YDE-044	(4-Me)Pro Gly Gln Leu Gly Leu Ala Gly Pro Lys
YDE-045	(5-Me)Pro Gly Gln Leu Gly Leu Ala Gly Pro Lys
YDE-048	Hyp Ala Gln Leu Gly Leu Ala Gly Pro Lys
YDE-049	Hyp Gly Ala Leu Gly Leu Ala Gly Pro Lys
YDE-054	Hyp Gly Gln Leu Gly Leu Ala Ala Pro Lys

YDE-057	 D-Hyp Gly Gln Leu Gly Leu Ala Gly Pro Lys (2R,4S)
YDE-058	 D-Hyp Gly D-Gln D-Leu Gly D-Leu D-Ala Gly D-Pro D-Lys (2R,4S)

8. The composition of claim 1, wherein the compound is selected from the following table:







YDE-011	 Hyp Gly Gln Leu Gly Leu Ala Gly Pro Lys (2S,4R)
YDE-048	 Hyp Ala Gln Leu Gly Leu Ala Gly Pro Lys
YDE-060	 D-Hyp Gly D-Gln D-Leu Gly D-Leu D-Ala Gly D-Pro D-Lys (2R,4R)







9. The composition of claim 8, wherein the compound has the structure:



10. Use of a composition comprising a salt of a compound selected from the following table:


YDE-001	Hyp Gly Gln Glu Gly Leu Ala Gly Pro Lys NH₂ (2S,4R)
YDE-008	Hyp Gly Gln Ala Gly Leu Ala Gly Pro Lys NH₂ (2S,4R)
YDE-011	Hyp Gly Gln Leu Gly Leu Ala Gly Pro Lys NH₂ (2S,4R)
YDE-015	Hyp Gly Gln Asp Val Leu Ala Gly Pro Lys NH₂ (2S,4R)

YDE-016	 Hyp Gly Gln Asp Ile Leu Ala Gly Pro Lys (2S,4R)
YDE-023	 Hyp Gly Gln Asp Ser Leu Ala Gly Pro Lys (2S,4R)
YDE-026	 Hyp Gly Gln Homo-Ser Gly Leu Ala Gly Pro Lys (2S,4R)
YDE-038	 (4-hydroxyMe)Pro Gly Gln Leu Gly Leu Ala Gly Pro Lys (2S,4R)
YDE-044	 (4-Me)Pro Gly Gln Leu Gly Leu Ala Gly Pro Lys
YDE-045	 (5-Me)Pro Gly Gln Leu Gly Leu Ala Gly Pro Lys

YDE-048	 Hyp Ala Gln Leu Gly Leu Ala Gly Pro Lys
YDE-049	 Hyp Gly Ala Leu Gly Leu Ala Gly Pro Lys
YDE-054	 Hyp Gly Gln Leu Gly Leu Ala Ala Pro Lys
YDE-057	 D-Hyp (2R,4S) Gly Gln Leu Gly Leu Ala Gly Pro Lys
YDE-058	 D-Hyp (2R,4S) Gly D-Gln D-Leu Gly D-Leu D-Ala Gly D-Pro D-Lys
YDE-060	 D-Hyp (2R,4R) Gly D-Gln D-Leu Gly D-Leu D-Ala Gly D-Pro D-Lys







wherein at least 90% of the compound in the composition is present as the salt;
in the manufacture of a medicament for the treatment of dry eye syndrome.







11. The use according to claim 10, wherein the compound has the structure:



12. An ophthalmic formulation comprising a composition comprising a salt of a compound selected from the following table:

YDE-001	Hyp Gly Gln Glu Gly Leu Ala Gly Pro Lys (2S,4R)
YDE-008	Hyp Gly Gln Ala Gly Leu Ala Gly Pro Lys (2S,4R)
YDE-011	Hyp Gly Gln Leu Gly Leu Ala Gly Pro Lys (2S,4R)
YDE-015	Hyp Gly Gln Asp Val Leu Ala Gly Pro Lys (2S,4R)


YDE-016	 Hyp Gly Gln Asp Ile Leu Ala Gly Pro Lys (2<i>S</i>,4<i>R</i>)
YDE-023	 Hyp Gly Gln Asp Ser Leu Ala Gly Pro Lys (2<i>S</i>,4<i>R</i>)
YDE-026	 Hyp Gly Gln Homo-Ser Gly Leu Ala Gly Pro Lys (2<i>S</i>,4<i>R</i>)
YDE-038	 (4-hydroxyMe)Pro Gly Gln Leu Gly Leu Ala Gly Pro Lys (2<i>S</i>,4<i>R</i>)
YDE-044	 (4-Me)Pro Gly Gln Leu Gly Leu Ala Gly Pro Lys
YDE-045	 (5-Me)Pro Gly Gln Leu Gly Leu Ala Gly Pro Lys

YDE-048	 Hyp Ala Gln Leu Gly Leu Ala Gly Pro Lys
YDE-049	 Hyp Gly Ala Leu Gly Leu Ala Gly Pro Lys
YDE-054	 Hyp Gly Gln Leu Gly Leu Ala Ala Pro Lys
YDE-057	 D-Hyp (2R,4S) Gly Gln Leu Gly Leu Ala Gly Pro Lys
YDE-058	 D-Hyp (2R,4S) Gly D-Gln D-Leu Gly D-Leu D-Ala Gly D-Pro D-Lys
YDE-060	 D-Hyp (2R,4R) Gly D-Gln D-Leu Gly D-Leu D-Ala Gly D-Pro D-Lys

wherein at least 90% of the compound in the composition is present as the salt; and a pharmaceutically acceptable excipient or carrier.

13. The ophthalmic formulation according to claim 12, wherein the ophthalmic formulation is an eye drop.







14. The ophthalmic formulation according to claim 12 or 13, wherein the compound has the structure:










15. A kit comprising:

(1) a composition comprising a salt of a compound selected from the following table:

YDE-001	Hyp Gly Gln Glu Gly Leu Ala Gly Pro Lys (2S,4R)
YDE-008	Hyp Gly Gln Ala Gly Leu Ala Gly Pro Lys (2S,4R)
YDE-011	Hyp Gly Gln Leu Gly Leu Ala Gly Pro Lys (2S,4R)


YDE-015	 Hyp Gly Gln Asp Val Leu Ala Gly Pro Lys (2S,4R)
YDE-016	 Hyp Gly Gln Asp Ile Leu Ala Gly Pro Lys (2S,4R)
YDE-023	 Hyp Gly Gln Asp Ser Leu Ala Gly Pro Lys (2S,4R)
YDE-026	 Hyp Gly Gln Homo-Ser Gly Leu Ala Gly Pro Lys (2S,4R)
YDE-038	 (4-hydroxyMe)Pro Gly Gln Leu Gly Leu Ala Gly Pro Lys (2S,4R)
YDE-044	 (4-Me)Pro Gly Gln Leu Gly Leu Ala Gly Pro Lys

YDE-045	 (5-Me)Pro Gly Gln Leu Gly Leu Ala Gly Pro Lys
YDE-048	 Hyp Ala Gln Leu Gly Leu Ala Gly Pro Lys
YDE-049	 Hyp Gly Ala Leu Gly Leu Ala Gly Pro Lys
YDE-054	 Hyp Gly Gln Leu Gly Leu Ala Ala Pro Lys
YDE-057	 D-Hyp (2R,4S) Gly Gln Leu Gly Leu Ala Gly Pro Lys
YDE-058	 D-Hyp (2R,4S) Gly D-Gln D-Leu Gly D-Leu D-Ala Gly D-Pro D-Lys



wherein at least 90% of the compound in the composition is present as the salt; and
(2) instructions for administration of the composition.

16. The kit according to claim 15, wherein the compound has the structure:



17. A kit comprising an ophthalmic formulation according to any one of claims 12-14; and
instructions for administration of the ophthalmic formulation.